Correlation of regional wall motion abnormalities detected by two-dimensional echocardiography with perfusion defect determined by technetium 99m sestamibi imaging in patients treated with reperfusion therapy during acute myocardial infarction.

Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print Cited Medium: Print ISSN: 0002-8703 (Print) Linking ISSN: 00028703 NLM ISO Abbreviation: Am Heart J Subsets: MEDLINE

Original Publication: St. Louis, MO : Mosby

Angioplasty, Balloon, Coronary* ; Coronary Circulation* ; Echocardiography* ; Myocardial Contraction* ; Technetium Tc 99m Sestamibi* ; Thrombolytic Therapy*; Myocardial Infarction/*drug therapy ; Myocardial Infarction/*therapy; Adult ; Aged ; Electrocardiography ; Female ; Fibrinolytic Agents/therapeutic use ; Heart Ventricles/diagnostic imaging ; Humans ; Male ; Middle Aged ; Myocardial Infarction/diagnostic imaging ; Patient Discharge ; Risk Factors ; Tissue Plasminogen Activator/therapeutic use ; Tomography, Emission-Computed, Single-Photon

Twenty patients (13 men and 7 women; mean age 61 +/- 12 years) with > 30 minutes chest pain and new ST-segment elevation who were treated with reperfusion therapy underwent technetium 99m sestamibi imaging and two-dimensional echocardiography simultaneously before and within 2 hours of each test after acute reperfusion therapy. Nine patients had anterior wall myocardial infarction. Fifteen patients were initially treated with intravenous thrombolytic agents, and five patients underwent urgent percutaneous transluminal coronary angioplasty. Both myocardial perfusion defect and wall motion score index (WMSI) improved after reperfusion therapy (perfusion defect from 28% to 15%, WMSI from 1.68 to 1.45, respectively; p < 0.005). The overall correlation between WMSI and perfusion defect as a measure of myocardium at risk was significant during the acute phase (r = 0.71) and at hospital dismissal (r = 0.71). Thus myocardial perfusion defect and wall motion abnormalities correlated fairly well in patients with acute myocardial infarction during the acute phase and at predismissal study.

0 (Fibrinolytic Agents)
971Z4W1S09 (Technetium Tc 99m Sestamibi)
EC 3.4.21.68 (Tissue Plasminogen Activator)

Date Created: 19960101 Date Completed: 19960220 Latest Revision: 20190626

20231215

10.1016/s0002-8703(96)90047-2

8554016